amgen glp-1 obesity drug market potential 2025 How to Invest in Drugs: Stocks and Funds to Watch GLP-1 Agonists Weight Loss Drugs
Description
Prices are already falling
For example, semaglutide 2.4 mg (Wegovy) yields approximately 15% body weight reduction in clinical trials, while lower doses used for diabetes (Ozempic) produce more modest weight loss
The company is also developing a preclinical conjugate combining both incretins and Myosin signalling blockers
Baseline demographic information, medical history, and lifestyle factors were requested at the initiation of the program
"Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis"
